Strategic R&D transactions in personalized drug development

Area of Science:

• Pharmaceutical industry
• Personalized medicine
• Biotechnology

Background:

• External collaboration is crucial for personalized medicine development.
• However, specific interorganizational transactions within the pharmaceutical sector remain under-explored.

Purpose of the Study:

• To investigate trends in strategic transactions and identify key players in pharmaceutical industry collaborations.
• To analyze the relationship between various transaction types and financing deals in personalized medicine.

Main Methods:

• Longitudinal survey of strategic transactions in the pharmaceutical industry.
• Comparative analysis with advanced medical developments (e.g., antibody therapy).
• Correlation and regression analyses to identify determinants of financing deals.

Main Results:

• A significant surge in start-up financing deals over the past decade, accelerating intellectual property (IP) creation.
• Patents showed a positive correlation with transactions.
• The number of research and development (R&D) licenses significantly predicted financing deals.

Conclusions:

• Start-ups and investors are identified as the primary drivers of progress in personalized medicine.
• Intellectual property creation and specific licensing agreements are critical factors in this advancement.